Most people diagnosed with kidney cancer today will survive at least five years. The overall five-year relative survival rate for kidney cancer is 78.6%, largely because the majority of cases are caught while the tumor is still confined to the kidney. But that number is an average across all stages, and your individual outlook depends heavily on how far the cancer has spread, the type of kidney cancer you have, your age, and how it’s treated.
Survival Rates by Stage
Stage at diagnosis is the single biggest factor in how long you can expect to live with kidney cancer. The numbers below are five-year relative survival rates, meaning they compare kidney cancer patients to people of the same age in the general population.
- Localized (confined to the kidney): 93%. This includes stage I and most stage II tumors. Surgery cures more than half of stage I patients outright.
- Regional (spread to nearby lymph nodes or tissues): Survival drops significantly once the cancer extends beyond the kidney capsule, though many patients still live years after diagnosis.
- Distant/metastatic (stage IV): This is where outcomes are most challenging. Median survival for stage IV kidney cancer was about 8 months for patients diagnosed between 2004 and 2010. By 2016 to 2019, that had climbed to 13.5 months, thanks largely to newer treatments.
These statistics are based on people diagnosed between 2015 and 2021, so they already reflect many modern treatments. But they also look backward. Someone diagnosed today may do better than these numbers suggest, especially for advanced disease where treatment options continue to expand.
How Cancer Subtype Affects Outlook
Not all kidney cancers behave the same way. About 70% of cases are clear cell renal cell carcinoma, which tends to be more aggressive. Chromophobe renal cell carcinoma, a less common subtype, carries a notably better prognosis: its five-year overall survival rate is about 90%, compared to roughly 75% for clear cell. Even after adjusting for tumor size, stage, age, and sex, chromophobe patients have about half the risk of dying from their cancer compared to clear cell patients. Papillary renal cell carcinoma falls somewhere in between, though it also generally does better than clear cell.
Your pathology report will identify which subtype you have, and it’s worth asking about because it meaningfully shapes what to expect.
Age and Survival
Younger patients consistently do better. Eight-year cancer-specific survival is about 80% for people diagnosed at age 49 or younger, drops to around 71% for those between 50 and 64, and falls to 56% for people aged 75 to 84. Part of this gap reflects biology: younger patients tend to have smaller, less aggressive tumors and tolerate surgery and other treatments more easily. But even within the same stage and tumor type, younger age is independently associated with better outcomes.
What Surgery Means for Long-Term Survival
For localized kidney cancer, surgery is the primary treatment and often the only one needed. There are two main options: removing just the tumor and a margin of healthy tissue (partial nephrectomy) or removing the entire kidney (radical nephrectomy). For early-stage tumors, partial nephrectomy offers a meaningful survival advantage. One large study of older patients with early-stage disease found that partial nephrectomy improved predicted survival by about 12 percentage points at five years and 15.5 percentage points at eight years compared to removing the whole kidney. In practical terms, treating seven patients with a partial rather than radical nephrectomy would prevent one death over eight years of follow-up.
The survival benefit likely comes from preserving kidney function. Losing an entire kidney increases the long-term risk of cardiovascular disease and chronic kidney disease, both of which can shorten life independently of cancer. If your tumor is small enough, partial nephrectomy is generally the preferred approach.
Recurrence After Surgery
Even after successful surgery for a tumor confined to the kidney, there’s a real risk of the cancer coming back. Roughly 20% to 30% of localized kidney cancers recur within five years. The risk varies by tumor size.
For the smallest tumors (stage T1a, 4 cm or less), 10-year recurrence-free survival is about 94.5%. For medium tumors (T1b, 4 to 7 cm), it drops to 75%. For larger tumors still confined to the kidney (T2, over 7 cm), it’s around 58% at 10 years. One important quirk of kidney cancer is that it can come back very late. Some patients in studies experienced recurrence more than 10 years after surgery. For small tumors, the annual recurrence risk after the five-year mark is about 0.5% per year. For medium and larger tumors, it’s closer to 3% per year even beyond five years. This is why long-term follow-up with imaging is standard after kidney cancer surgery, often extending well beyond the typical five-year surveillance window used for other cancers.
How New Treatments Have Changed Advanced Kidney Cancer
The outlook for stage IV kidney cancer has improved substantially over the past 15 years. Median survival for metastatic kidney cancer rose from about 8 months (2004 to 2010) to 13.5 months (2016 to 2019), one of the largest survival gains seen across all common metastatic cancers during that period. This improvement is tied directly to the rise of immunotherapy and targeted therapies. The share of kidney cancer patients receiving immunotherapy jumped from about 5% in the earlier period to 35% by 2016 to 2019.
For patients with metastatic disease, doctors use a risk scoring system that accounts for factors like how quickly the cancer grew, blood counts, and overall health to group patients into favorable, intermediate, or poor risk categories. Patients in the favorable risk group have a median survival of about 43 months, or roughly three and a half years. Intermediate and poor risk groups have shorter median survival times, but the newer combination therapies have pushed these numbers upward compared to a decade ago.
Some patients with metastatic kidney cancer who respond well to immunotherapy achieve durable remissions lasting years. This is still the exception rather than the rule, but it represents a real shift from the era when metastatic kidney cancer had very few effective treatment options.
Factors That Influence Your Individual Outlook
Survival statistics describe populations, not individuals. Several factors tilt the odds in one direction or the other:
- Tumor stage and size: The most powerful predictor. A small, localized tumor has a fundamentally different trajectory than one that has spread to the lungs or bones.
- Cancer subtype: Chromophobe and papillary types generally carry a better prognosis than clear cell.
- Age and overall health: Younger, healthier patients tolerate treatment better and have higher survival rates at every stage.
- Response to treatment: For advanced disease, how well the cancer responds to initial therapy strongly predicts long-term outcomes. Patients who achieve significant tumor shrinkage early tend to live longer.
- Kidney function: Preserving as much healthy kidney tissue as possible during surgery protects against cardiovascular and metabolic complications that can independently affect lifespan.
The five-year survival benchmarks are useful for understanding the general picture, but kidney cancer’s tendency toward late recurrence means that even patients who pass the five-year mark benefit from continued monitoring. For early-stage patients who remain cancer-free, the long-term outlook is excellent. For those with advanced disease, the treatment landscape is improving faster than for most other cancers.